Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xbiome, an AI Company, Completes B+ Round for Microbiome Trials

publication date: Nov 30, 2020

Shenzhen Xbiome, which uses AI to develop microbiome products, raised "tens of million dollars" in a Series B+ round to support development of its gut bacteria therapies. The company is ready to start tests in 2021 of fecal microbiota transplantation (FMT) capsules that treat autism and graft-versus-host disease (GvHD). The programs have already started China investigator-initiated trials. The B+ round was led by Primavera Capital and Gaorong Capital, with existing investors Legend Capital and 5Y (formerly Morningside Venture) participating. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital